{
    "ticker": "RNLX",
    "name": "Renalytix AI, Inc.",
    "description": "Renalytix AI, Inc. is a pioneering healthcare company focused on advancing the diagnosis and management of kidney disease through artificial intelligence and machine learning. Founded in 2018, Renalytix combines proprietary AI technology with clinical insights to facilitate early detection of kidney disease and improve patient outcomes. The company's flagship product, KidneyIntelX, is a groundbreaking diagnostic platform that enhances clinical decision-making by providing actionable insights based on patient data. This platform is designed to identify patients at risk for progressive kidney disease and help healthcare providers tailor treatment plans accordingly. Renalytix is committed to transforming kidney care through innovation, emphasizing early intervention that can lead to significant improvements in health outcomes and cost savings for healthcare systems. With the prevalence of chronic kidney disease increasing globally, Renalytix aims to fill a critical gap in the current healthcare landscape by leveraging technology to empower patients and clinicians alike. The company collaborates with leading healthcare institutions and researchers to validate its technologies and expand its offerings, ultimately striving to become a leader in kidney health management.",
    "industry": [
        "Healthcare",
        "Biotechnology"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.renalytixai.com",
    "ceo": "James McCullough",
    "social_media": {
        "twitter": "https://twitter.com/RenalytixAI",
        "linkedin": "https://www.linkedin.com/company/renalytixai/"
    },
    "investor_relations": "https://investors.renalytixai.com",
    "key_executives": [
        {
            "name": "James McCullough",
            "position": "CEO"
        },
        {
            "name": "David A. Schwartz",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Solutions",
            "products": [
                "KidneyIntelX"
            ]
        }
    ],
    "seo": {
        "meta_title": "Renalytix AI, Inc. | Advancing Kidney Disease Management",
        "meta_description": "Explore Renalytix AI, Inc., a leader in kidney disease diagnostics using advanced AI technology to improve patient outcomes.",
        "keywords": [
            "Renalytix",
            "Kidney Disease",
            "AI Diagnostics",
            "Healthcare Innovation",
            "KidneyIntelX"
        ]
    },
    "faq": [
        {
            "question": "What does Renalytix AI do?",
            "answer": "Renalytix AI focuses on the diagnosis and management of kidney disease using artificial intelligence and advanced data analytics."
        },
        {
            "question": "What is KidneyIntelX?",
            "answer": "KidneyIntelX is Renalytix's flagship diagnostic platform designed to enhance the detection and management of kidney disease."
        },
        {
            "question": "When was Renalytix AI founded?",
            "answer": "Renalytix AI was founded in 2018."
        },
        {
            "question": "Where is Renalytix AI headquartered?",
            "answer": "Renalytix AI is headquartered in New York, New York, USA."
        }
    ],
    "competitors": [
        "DGX",
        "LH"
    ],
    "related_stocks": [
        "ABT",
        "MDT",
        "ISRG",
        "BAX"
    ]
}